Acumen Pharmaceuticals(ABOS)
Focus: Acumen Pharmaceuticals is a newly public (2024) neurology-focused biotech developing Alzheimer's disease therapeutics centered on monoclonal antibody technology. The company operates as a clinical-stage entity with a lean 1-50 person team headquartered in Newton, MA.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
0
About Acumen Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Acumen Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Acumen Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACU193
Alzheimer DiseaseClinical Trials (2)
NCT04931459A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
Phase 1Help build intelligence for Acumen Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.